Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
- PMID: 29285544
- DOI: 10.1001/jamaoncol.2017.4182
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
Erratum in
-
Missing Conflict of Interest Disclosure.JAMA Oncol. 2018 Oct 1;4(10):1439. doi: 10.1001/jamaoncol.2018.4091. JAMA Oncol. 2018. PMID: 30128482 Free PMC article. No abstract available.
Comment in
-
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply.JAMA Oncol. 2018 Sep 1;4(9):1300-1301. doi: 10.1001/jamaoncol.2018.1715. JAMA Oncol. 2018. PMID: 29978197 No abstract available.
-
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies.JAMA Oncol. 2018 Sep 1;4(9):1299-1300. doi: 10.1001/jamaoncol.2018.1709. JAMA Oncol. 2018. PMID: 29978198 No abstract available.
-
Inconsistent Reporting of Potential Conflicts of Interest.JAMA Oncol. 2018 Oct 1;4(10):1439. doi: 10.1001/jamaoncol.2018.3461. JAMA Oncol. 2018. PMID: 30128488 No abstract available.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical